Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 4/2015

Open Access 01-12-2015 | CLINICAL

Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?

Authors: Gouji Toyokawa, Takashi Seto, Mitsuhiro Takenoyama, Yukito Ichinose

Published in: Cancer and Metastasis Reviews | Issue 4/2015

Login to get access

Abstract

Anaplastic lymphoma kinase (ALK) has been identified to exert a potent transforming activity through its rearrangement in non-small cell lung cancer (NSCLC), and patients (pts) with ALK rearrangement can be treated more successfully with ALK inhibitors, such as crizotinib, alectinib, and ceritinib, than with chemotherapy. Despite the excellent efficacy of ALK inhibitors, resistance to these drugs is inevitably encountered in most ALK-rearranged pts. Cases of resistance are subtyped into three groups, i.e., systemic, oligo, and central nervous system (CNS) types, with the CNS being used to be considered a sanctuary. With regard to the management of CNS lesions in pts with ALK+ NSCLC, a growing body of evidence has gradually demonstrated the intracranial (IC) efficacy of ALK inhibitor (ALKi) in ALK+ NSCLC pts with brain metastases (BMs). Although the efficacy of crizotinib for the CNS lesions remains controversial, a recent retrospective investigation of ALK+ pts with BM enrolled in PROFILE 1005 and PROFILE 1007 demonstrated that crizotinib is associated with a high disease control rate for BM. However, BM comprises the most common site of progressive disease in pts with or without baseline BMs, which is a serious problem for crizotinib. Furthermore, alectinib can be used to achieve strong and long-lasting inhibitory effects on BM. In addition to alectinib, the IC efficacy of other next-generation ALK inhibitors, such as ceritinib, AP26113 and PF-06463922, has been demonstrated. In this article, we review the latest evidence regarding the BM and IC efficacy of ALK inhibitors in pts with ALK+ NSCLC.
Literature
1.
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448(7153), 561–566.CrossRefPubMed
2.
Gainor, J. F., Varghese, A. M., Ou, S. H., Kabraji, S., Awad, M. M., Katayama, R., et al. (2013). ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clinical Cancer Research, 19(15), 4273–4281.CrossRefPubMed
3.
Kwak, E. L., Bang, Y. J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., et al. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. The New England Journal of Medicine, 363(18), 1693–1703.PubMedCentralCrossRefPubMed
4.
Camidge, D. R., Bang, Y. J., Kwak, E. L., Iafrate, A. J., Varella-Garcia, M., Fox, S. B., et al. (2012). Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. The Lancet Oncology, 13(10), 1011–1019.PubMedCentralCrossRefPubMed
5.
Shaw, A. T., Kim, D. W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M. J., et al. (2013). Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. The New England Journal of Medicine, 368(25), 2385–2394.CrossRefPubMed
6.
Solomon, B. J., Mok, T., Kim, D. W., Wu, Y. L., Nakagawa, K., Mekhali, T., et al. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England Journal of Medicine, 371(23), 2167–2177.CrossRefPubMed
7.
Seto, T., Kiura, K., Nishio, M., Nakagawa, K., Maemondo, M., Inoue, A., et al. (2013). CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. The Lancet Oncology, 14(7), 590–598.CrossRefPubMed
8.
Gadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A. A., West, H. L., Azada, H. L., et al. (2014). Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding proportion of a phase 1/2 study. The Lancet Oncology, 15(10), 1119–1128.CrossRefPubMed
9.
Shaw, A. T., Kim, D. W., Mehra, R., Tan, D. S., Felip, E., Chow, L. Q., et al. (2014). Ceritinib for ALK-rearranged non-small-cell lung cancer. The New England Journal of Medicine, 370(13), 1189–1197.PubMedCentralCrossRefPubMed
10.
Barnholtz-Sloan, J. S., Sloan, A. E., Davis, F. G., Vigneau, F. D., Lai, P., & Sawaya, R. E. (2004). Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. Journal of Clinical Oncology, 22(14), 2865–2872.CrossRefPubMed
11.
Schouten, L. J., Rutten, J., Huveneers, H. A., & Twijnstra, A. (2002). Incidence of brain metastases in a cohort of carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer, 94(10), 2698–2705.CrossRefPubMed
12.
Arrieta, O., Saavedera-Perez, D., Kuri, R., Aviles-Salas, A., Martinez, L., Mendoza-Posada, D., et al. (2009). Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC Cancer. doi:10.​1186/​1471-2407-9-119.PubMedCentralPubMed
13.
Hanna, N. H., Dahlberg, S. E., Kolesar, J. M., Aggarwal, C., Hirsch, F. R., Ramalingam, S. S., et al. (2015). Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced nonsmall cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: an Eastern Cooperative Oncology Group (ECOG) study (E4508). Cancer. doi:10.​1002/​cncr.​29308.
14.
Doebele, R. C., Lu, X., Sumey, C., Maxson, D. A., Weickhardt, A. J., Oton, A. B., et al. (2012). Oncogene status predicts patterns of metastatic spread in treatment-naïve nonsmall cell lung cancer. Cancer, 118(18), 4502–4511.PubMedCentralCrossRefPubMed
15.
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E., Mahadevan, A., Floyd, S. T., et al. (2015). Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer, 88(1), 108–111.CrossRefPubMed
16.
Felip, E., Orlov, S., Park, K., Yu, CJ., Tsai, CM., Nishio, M., et al. (2015). ASCEND-3: a single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol, 33(supple; abstr 8060).
17.
Shaw, A., Mehra, R., Tan, D., Felip, E., Chow, L. Q., Camidge, D. R., et al. (2014). Evaluation of ceritinib-treated patients with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases in the ASCEND-1 study. Annals of Oncology, 2(4), iv426–iv470. doi:10.​1093/​annonc/​mdu349.
18.
Mok, T., Spigel, D., Felip, E., Ahn, MJ., Groen, MJA., Wakelee, HA., et al. (2015). ASCEND-2: a single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). J Clin Oncol, 33(supple; abstr 8059).
19.
Ou, SH., Ahn, JS., Petris, LD., Govindan, R., Yang, JCH., Hughes, BGM., et al. (2015). Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: an open-label, single-arm, global phase 2 study (NP28673). J Clin Oncol, 33(supple; abstr 8008).
20.
Gandhi, L., Shaw, A., Gadgeel, SM., Riely, G., Cetnar, J., West, HJ., et al. (2015). A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). J Clin Oncol, 33(supple; abstr 8019).
21.
Camidge, DR., Bazhenova, L., Salgia, R., Langer, CJ., Gold, KA., Rosell, R., et al. (2015). Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). J Clin Oncol, 33(supple; abstr 8062).
22.
Costa, D. B., Shaw, A. T., Ou, S. H., Solomon, B. J., Riely, G. J., Ahn, M. J., et al. (2015). Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. Journal of Clinical Oncology, 33(17), 1881–1888.CrossRefPubMed
23.
Ajimizu, H., Kim, Y. H., & Mishima, M. (2015). Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib. Medical Oncology, 32(2), 477.CrossRefPubMed
24.
Ou, S. H., Sommers, K. R., Azada, M. C., Garon, E. B., et al. (2015). Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis. The Oncologist, 20(2), 224–226.CrossRefPubMed
25.
Gainor, J. F., Sherman, C. A., Willoughby, K., Logan, J., Kennedy, E., Brastianos, P. K., et al. (2015). Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. Journal of Thoracic Oncology, 10(2), 232–236.CrossRefPubMed
26.
Kodama, T., Hasegawa, M., Takanashi, K., Sakurai, Y., Kondoh, O., & Sakamoto, H. (2014). Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemotherapy and Pharmacology, 74(5), 1023–1028.CrossRefPubMed
27.
Nanjo, S., Nakagawa, T., Takeuchi, S., Kita, K., Fukuda, K., Nakada, M., et al. (2015). In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Science, 106(3), 244–252.PubMedCentralCrossRefPubMed
28.
Shaw, AT., Bauer, TM., Felip, E., Besse, B., James, LP., Clancy, JS., et al. (2015). Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC. J Clin Oncol, 33(supple; abstr 8018).
29.
Sperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., et al. (2012). Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. Journal of Clinical Oncology, 30(4), 419–25.PubMedCentralCrossRefPubMed
30.
Iwahara, T., Fujimoto, J., Wen, D., Cupples, R., Bucay, N., Arakawa, T., et al. (1997). Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene, 14(4), 439–449.CrossRefPubMed
31.
Weickhardt, A. J., Scheier, B., Burke, J. M., Gan, G., Lu, X., Bunn, P. A., Jr., et al. (2012). Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. Journal of Thoracic Oncology, 7(12), 1807–1814.PubMedCentralCrossRefPubMed
32.
Nieder, C., Grosu, A. L., Astner, S., Thamm, R., & Molls, M. (2006). Integration of chemotherapy into current treatment strategies for brain metastases from solid tumors. Radiation Oncology, 1, 19.PubMedCentralCrossRefPubMed
33.
Sekine, A., Satoh, H., Iwasawa, T., Tamura, K., Hayashihara, K., Saito, T., et al. (2014). Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy. Medical Oncology. doi:10.​1007/​s12032-014-0228-9.PubMed
34.
Togashi, Y., Masago, K., Masuda, S., Mizuno, T., Fukudo, M., Ikemi, Y., et al. (2012). Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemotherapy Pharmacology, 70(2012), 399–405.CrossRefPubMed
35.
Omuro, A. M., Kris, M. G., Miller, V. A., Franceschi, E., Shah, N., Milton, D., et al. (2005). High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer, 103(11), 2344–2348.CrossRefPubMed
36.
Iuchi, T., Shingyouji, M., Sakaida, T., Hatano, K., Nagano, O., Itakura, M., et al. (2013). Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer, 82(2), 282–287.CrossRefPubMed
37.
Heon, S., Yeap, B. Y., Lindeman, N. I., Joshi, V. A., Butaney, M., Britt, G. J., et al. (2012). The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer. Clinical Cancer Research, 18(16), 4406–4414.PubMedCentralCrossRefPubMed
38.
Park, K., Ahn, M., Yu, C., Kim, S., Lin, M., Sriuranpong, V., et al. (2014). ASPIRATION: first-line erlotinib (E) until and beyond RECIST progression (PD) in Asian patients (pts) with EGFR mutation-positive (mut+) NSCLC. Annals of Oncology, 25(4), iv426–iv470. doi:10.​1093/​annonc/​mdu349.
39.
Kaneda, H., Okamoto, I., & Nakagawa, K. (2013). Rapid response of brain metastases to crizotinib in a patients with ALK rearrangement-positive non-small-cell lung cancer. Journal of Thoracic Oncology, 8(4), e32–33.CrossRefPubMed
40.
Kinoshita, Y., Koga, Y., Sakamoto, A., & Hidaka, K. (2013). Long-lasting response to crizotinib in brain metastases due to EML4-ALK-rearranged non-small-cell lung cancer. BMJ Case Report. doi:10.​1136/​bcr-2013-200867.
41.
Peled, N., Zach, L., Liran, O., Ilouze, M., Bunn, P. A., Jr., & Hirsch, F. R. (2013). Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer. Journal of Thoracic Oncology, 8(12), e112–e113.CrossRefPubMed
42.
Kim, Y. H., Ozasa, H., Nagai, H., Sakamori, Y., Yoshida, H., Yagi, Y., et al. (2013). High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. Journal of Thoracic Oncology, 8(9), e85–86.CrossRefPubMed
43.
Costa, D. B., Kobayashi, S., Pandya, S. S., Yeo, W. L., Shen, Z., Tan, W., et al. (2011). CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. Journal of Clinical Oncology, 29(15), e443–e445.CrossRefPubMed
44.
Chun, S. G., Choe, K. S., Iyengar, P., Yordy, J. S., & Timmerman, R. D. (2012). Isolated central nervous system progression on crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biology and Therapy, 13(14), 1376–1383.PubMedCentralCrossRefPubMed
45.
Gainor, J. F., Ou, S. H., Logan, J., Borges, L. F., & Shaw, A. T. (2013). The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. Journal of Thoracic Oncology, 8(12), 1570–1573.CrossRefPubMed
46.
Metro, G., Lunardi, G., Floridi, P., Pascali, J. P., Marcomigni, L., Chiari, R., et al. (2015). CSF concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment. Journal of Thoracic Oncology, 10(5), e26–27.CrossRefPubMed
47.
Sakamoto, H., Tsukaguchi, T., Hiroshima, S., Kodama, T., Kobayashi, T., Fukami, T. A., et al. (2011). CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell, 19(5), 679–690.CrossRefPubMed
48.
Kodama, T., Tsukaguchi, T., Satoh, Y., Yoshida, M., Watanabe, Y., Kondoh, O., et al. (2014). Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Molecular Cancer Therapeutics, 13(12), 2910–2918.CrossRefPubMed
49.
Kodama, T., Tsukaguchi, T., Yoshida, M., Kondoh, O., & Sakamoto, H. (2014). Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Letters, 351(2), 215–221.CrossRefPubMed
50.
Bartels, A. L., Kortekaas, R., Bart, J., Willemsen, A. T., de Klerk, O. L., de Vries, J. J., et al. (2009). Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiology of Aging, 30(11), 1818–1824.CrossRefPubMed
51.
Ohe, Y., Nishio, M., Kiura, K., Seto, T., Nakagawa, K., Maemondo, M., et al. (2015). A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK+ NSCLC) patients (pts): updates on progression free survival (PFS) and safety results from AF001JP. J Clin Oncol, 33(supple; abstr 8061).
52.
Ou, S. H., Klempner, S. J., Azada, M. C., Rausei-Mills, V., & Duma, C. (2015). Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: implications for disease assessment and management. Lung Cancer, 88(3), 355–359.CrossRefPubMed
53.
Seto, T., Hida, T., Nakagawa, K., Satouchi, M., Nishio, M., Hotta, K., et al. (2014). Anti-tumor activity of alectinib in crizotinib pre-treated ALK-rearranged NSCLC in JP28927 study. Annals of Oncology, 25(4), iv426–iv470. doi:10.​1093/​annonc/​mdu349.
54.
Friboulet, L., Li, N., Katayama, R., Lee, C. C., Gainor, J. F., Crystal, A. S., et al. (2014). The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discovery, 4(6), 662–673.PubMedCentralCrossRefPubMed
55.
Gainor, J. F., Tan, D. S., De Pas, T., Solomon, B. J., Ahmad, A., Lazzari, C., et al. (2015). Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib. Clinical Cancer Research, 21(12), 2745–2752.CrossRefPubMed
56.
Zykadia, C. (2014). US prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation.
57.
Zou, H. Y., Friboulet, L., Kodack, D. P., Engstrom, L. D., Li, Q., West, M., et al. (2015). PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell, 28(1), 70–81.CrossRefPubMed
58.
Horn, L., Infante, JR., Blumenschein, GR., Wakelee, HA., Arkenau, HT., Dukar, G., et al. (2014). A phase I trial of X-396, a novel inhibitor, in patients with advanced solid tumors. J Clin Oncol, 32:5s (supple; abstr 8030^).
59.
Arkenau, HT., Sachdev, JC., Mita, MM., Dziadziuszko, R., Lin, CC., Yang, JCH., et al. (2015). Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer. J Clin Oncol, 33(supple; abstr 8063).
60.
Gandara, D. R., Li, T., Lara, P. N., Kelly, K., Riess, J. W., Redman, M. W., et al. (2014). Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clinical Lung Cancer, 15(1), 1–6.PubMedCentralCrossRefPubMed
61.
Takeda, M., Okamoto, I., & Nakagawa, K. (2013). Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement. Journal of Thoracic Oncology, 8(5), 654–657.CrossRefPubMed
62.
Ou, S. H., Jänne, P. A., Bartlett, C. H., Tang, Y., Kim, D. W., Otterson, G. A., et al. (2014). Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Annals of Oncology, 25(2), 415–422.CrossRefPubMed
Metadata
Title
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Authors
Gouji Toyokawa
Takashi Seto
Mitsuhiro Takenoyama
Yukito Ichinose
Publication date
01-12-2015
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 4/2015
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-015-9592-y

Other articles of this Issue 4/2015

Cancer and Metastasis Reviews 4/2015 Go to the issue

NON-THEMATIC REVIEW

The origin of prostate metastases: emerging insights

Non-Thematic Review

Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities

NON-THEMATIC REVIEW

Neutrophils: important contributors to tumor progression and metastasis

NON-THEMATIC REVIEW

Protease-activated receptors (PARs)—biology and role in cancer invasion and metastasis

NON-THEMATIC REVIEW

Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies

NON-THEMATIC REVIEW

The challenge of targeting metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits